Literature DB >> 21196207

Signalling to cancer cell invasion through PAK family kinases.

Andrew Whale1, Fariesha Nur Hashim, Sally Fram, Gareth E Jones, Claire M Wells.   

Abstract

Cancer cell metastasis involves a series of changes in cell behaviour, driven by oncogenic transformation, that leads to local tissue invasion, migration through extracellular matrix, entry into the vascular or lymphatic system and colonisation of distant sites. It is well established that the Rho family GTPases Rho, Rac and Cdc42 orchestrate many of the processes required during metastasis. The Rho family GTPases regulate cellular behaviour through their interaction with downstream effector proteins. The p-21 activated kinases (PAKs), effector proteins for Rac and Cdc42, are known to be important regulators of cell migration and invasion. There are six mammalian PAKs which can be divided into two groups: group I PAKs (PAK1-3) and group II PAKs (PAK4-6). Although the two PAK groups are architecturally similar there are differences in their mode of regulation suggesting their cellular functions are likely to be different. This review will focus on the latest evidence relating to the role of PAK family kinases in the cell signalling pathways that drive cancer cell migration and invasion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196207     DOI: 10.2741/3724

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  48 in total

Review 1.  P21 activated kinases: structure, regulation, and functions.

Authors:  Chetan K Rane; Audrey Minden
Journal:  Small GTPases       Date:  2014-03-21

2.  Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics.

Authors:  Florian Gnad; Amy Young; Wei Zhou; Karen Lyle; Christy C Ong; Matthew P Stokes; Jeffrey C Silva; Marcia Belvin; Lori S Friedman; Hartmut Koeppen; Audrey Minden; Klaus P Hoeflich
Journal:  Mol Cell Proteomics       Date:  2013-04-22       Impact factor: 5.911

3.  Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.

Authors:  Brenda L Montalvo-Ortiz; Linette Castillo-Pichardo; Eliud Hernández; Tessa Humphries-Bickley; Alina De la Mota-Peynado; Luis A Cubano; Cornelis P Vlaar; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2012-03-01       Impact factor: 5.157

Review 4.  Molecular mechanisms of epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Jian Xu; Rik Derynck
Journal:  Nat Rev Mol Cell Biol       Date:  2014-03       Impact factor: 94.444

Review 5.  PI3K signaling in cancer: beyond AKT.

Authors:  Evan C Lien; Christian C Dibble; Alex Toker
Journal:  Curr Opin Cell Biol       Date:  2017-03-24       Impact factor: 8.382

6.  A novel PAK1 variant causative of neurodevelopmental disorder with postnatal macrocephaly.

Authors:  Sachiko Ohori; Satomi Mitsuhashi; Revital Ben-Haim; Eli Heyman; Toru Sengoku; Kazuhiro Ogata; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2020-01-31       Impact factor: 3.172

Review 7.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation.

Authors:  Michelle C Mendoza; E Emrah Er; John Blenis
Journal:  Trends Biochem Sci       Date:  2011-04-30       Impact factor: 13.807

8.  PAK5-mediated E47 phosphorylation promotes epithelial-mesenchymal transition and metastasis of colon cancer.

Authors:  G Zhu; X Li; B Guo; Q Ke; M Dong; F Li
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

Review 9.  Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition.

Authors:  Rik Derynck; Baby Periyanayaki Muthusamy; Koy Y Saeteurn
Journal:  Curr Opin Cell Biol       Date:  2014-09-18       Impact factor: 8.382

10.  Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.

Authors:  Christian Posch; Martina Sanlorenzo; Igor Vujic; Juan A Oses-Prieto; Brian D Cholewa; Sarasa T Kim; Jeffrey Ma; Kevin Lai; Mitchell Zekhtser; Rosaura Esteve-Puig; Gary Green; Shreya Chand; Alma L Burlingame; Renate Panzer-Grümayer; Klemens Rappersberger; Susana Ortiz-Urda
Journal:  J Invest Dermatol       Date:  2016-05-29       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.